Clinical features and mechanistic insights into drug repurposing for combating COVID-19.

Asrani, P; Tiwari, K; Eapen, MS; McAlinden, KD; Haug, G; Johansen, MD; Hansbro, PM; Flanagan, KL; Hassan, MI; Sohal, SS

Clinical features and mechanistic insights into drug repurposing for combating COVID-19.

Asrani, P Tiwari, K Eapen, MS McAlinden, KD Haug, G Johansen, MD Hansbro, PM Flanagan, KL Hassan, MI Sohal, SS

Permalink

Publisher:: PERGAMON-ELSEVIER SCIENCE LTD
Publication Type:: Journal Article
Citation:: Int J Biochem Cell Biol, 2022, 142, pp. 106114
Issue Date:: 2022-01

Closed Access

	Filename	Description	Size
	Clinical features and mechanistic insights into drug repurposing for combating COVID-19.pdf		3.97 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Asrani, P
dc.contributor.author	Tiwari, K
dc.contributor.author	Eapen, MS
dc.contributor.author	McAlinden, KD
dc.contributor.author	Haug, G
dc.contributor.author	Johansen, MD
dc.contributor.author	Hansbro, PM
dc.contributor.author	Flanagan, KL
dc.contributor.author	Hassan, MI
dc.contributor.author	Sohal, SS
dc.date.accessioned	2022-02-16T02:51:31Z
dc.date.available	2021-11-01
dc.date.available	2022-02-16T02:51:31Z
dc.date.issued	2022-01
dc.identifier.citation	Int J Biochem Cell Biol, 2022, 142, pp. 106114
dc.identifier.issn	1357-2725
dc.identifier.issn	1878-5875
dc.identifier.uri	http://hdl.handle.net/10453/154590
dc.description.abstract	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged from Wuhan in China before it spread to the entire globe. It causes coronavirus disease of 2019 (COVID-19) where mostly individuals present mild symptoms, some remain asymptomatic and some show severe lung inflammation and pneumonia in the host through the induction of a marked inflammatory 'cytokine storm'. New and efficacious vaccines have been developed and put into clinical practice in record time, however, there is a still a need for effective treatments for those who are not vaccinated or remain susceptible to emerging SARS-CoV-2 variant strains. Despite this, effective therapeutic interventions against COVID-19 remain elusive. Here, we have reviewed potential drugs for COVID-19 classified on the basis of their mode of action. The mechanisms of action of each are discussed in detail to highlight the therapeutic targets that may help in reducing the global pandemic. The review was done up to July 2021 and the data was assessed through the official websites of WHO and CDC for collecting the information on the clinical trials. Moreover, the recent research papers were also assessed for the relevant data. The search was mainly based on keywords like Coronavirus, SARS-CoV-2, drugs (specific name of the drugs), COVID-19, clinical efficiency, safety profile, side-effects etc.This review outlines potential areas for future research into COVID-19 treatment strategies.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	PERGAMON-ELSEVIER SCIENCE LTD
dc.relation.ispartof	Int J Biochem Cell Biol
dc.relation.isbasedon	10.1016/j.biocel.2021.106114
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0601 Biochemistry and Cell Biology, 1101 Medical Biochemistry and Metabolomics, 1116 Medical Physiology
dc.subject.classification	Biochemistry & Molecular Biology
dc.subject.mesh	Adaptive Immunity
dc.subject.mesh	Antibodies, Viral
dc.subject.mesh	Antimalarials
dc.subject.mesh	Antiparasitic Agents
dc.subject.mesh	Antiviral Agents
dc.subject.mesh	CD4-Positive T-Lymphocytes
dc.subject.mesh	COVID-19
dc.subject.mesh	Drug Repositioning
dc.subject.mesh	Humans
dc.subject.mesh	Immunity, Innate
dc.subject.mesh	Immunization, Passive
dc.subject.mesh	Probiotics
dc.subject.mesh	SARS-CoV-2
dc.subject.mesh	CD4-Positive T-Lymphocytes
dc.subject.mesh	Humans
dc.subject.mesh	Antibodies, Viral
dc.subject.mesh	Antiparasitic Agents
dc.subject.mesh	Antimalarials
dc.subject.mesh	Antiviral Agents
dc.subject.mesh	Immunization, Passive
dc.subject.mesh	Probiotics
dc.subject.mesh	Immunity, Innate
dc.subject.mesh	Adaptive Immunity
dc.subject.mesh	Drug Repositioning
dc.subject.mesh	COVID-19
dc.subject.mesh	SARS-CoV-2
dc.title	Clinical features and mechanistic insights into drug repurposing for combating COVID-19.
dc.type	Journal Article
utslib.citation.volume	142
utslib.location.activity	Netherlands
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1101 Medical Biochemistry and Metabolomics
utslib.for	1116 Medical Physiology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	closed_access	*
dc.date.updated	2022-02-16T02:51:24Z
pubs.publication-status	Published
pubs.volume	142

Abstract:

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged from Wuhan in China before it spread to the entire globe. It causes coronavirus disease of 2019 (COVID-19) where mostly individuals present mild symptoms, some remain asymptomatic and some show severe lung inflammation and pneumonia in the host through the induction of a marked inflammatory 'cytokine storm'. New and efficacious vaccines have been developed and put into clinical practice in record time, however, there is a still a need for effective treatments for those who are not vaccinated or remain susceptible to emerging SARS-CoV-2 variant strains. Despite this, effective therapeutic interventions against COVID-19 remain elusive. Here, we have reviewed potential drugs for COVID-19 classified on the basis of their mode of action. The mechanisms of action of each are discussed in detail to highlight the therapeutic targets that may help in reducing the global pandemic. The review was done up to July 2021 and the data was assessed through the official websites of WHO and CDC for collecting the information on the clinical trials. Moreover, the recent research papers were also assessed for the relevant data. The search was mainly based on keywords like Coronavirus, SARS-CoV-2, drugs (specific name of the drugs), COVID-19, clinical efficiency, safety profile, side-effects etc.This review outlines potential areas for future research into COVID-19 treatment strategies.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/154590